BridgeBio Pharma financials
$65.97−0.96%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $243.7M | $194.5M | $154.2M | $120.7M | $110.6M | $116.6M | $5.9M | $2.7M | $2.2M | $211.1M | $1.7M | $4.1M |
| Gross profit | $228.6M | $184.6M | $146.1M | $114.1M | $106.9M | $114.0M | $3.8M | $2.1M | $1.6M | $210.5M | $1.1M | $3.5M |
| Gross margin | 93.8% | 94.9% | 94.7% | 94.6% | 96.7% | 97.7% | 64.6% | 78.1% | 72.4% | 99.7% | 65.7% | 85.4% |
| Operating income | -$107.1M | -$106.0M | -$139.6M | -$145.2M | -$134.3M | -$104.4M | -$226.0M | -$191.8M | -$175.5M | $343.0K | -$177.4M | -$157.7M |
| Net income | -$152.2M | -$164.0M | -$192.9M | -$182.7M | -$181.9M | -$167.4M | -$265.1M | -$162.0M | -$73.5M | -$35.2M | -$168.1M | -$177.0M |
| Net margin | −62.5% | −84.3% | −125.1% | −151.4% | −164.5% | −143.5% | −4506.1% | −5931.2% | −3388.2% | −16.7% | −9636.0% | −4326.5% |
| Diluted EPS | $-0.78 | $-0.84 | $-1.00 | $-0.95 | $-0.95 | $-0.88 | $-1.40 | $-0.86 | $-0.39 | $-0.20 | $-0.96 | $-1.08 |
| EBITDA | -$106.0M | -$104.8M | -$127.0M | -$135.0M | -$132.2M | -$102.5M | -$220.0M | -$185.6M | -$171.1M | $5.3M | -$176.7M | -$155.8M |
| Operating cash flow | -$71.1M | -$197.3M | -$56.4M | -$109.6M | -$80.7M | -$199.2M | -$195.3M | -$180.6M | $74.7M | -$219.5M | -$124.8M | -$145.2M |
| Free cash flow | -$71.5M | -$197.3M | -$56.5M | -$110.0M | -$81.3M | -$199.2M | -$195.4M | -$180.7M | $74.6M | -$220.2M | -$125.3M | -$145.7M |
| Diluted shares | 195.8M | 194.8M | 193.6M | 191.9M | 190.5M | 190.1M | 189.5M | 188.5M | 187.6M | 178.7M | 174.7M | 163.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $677.9M | $879.9M | $570.1M | $643.0M | $749.0M | $540.6M |
| Short-term investments | $42.2M | $60.3M | $17.4M | $3.0M | $7.9M | $0.00 |
| Total debt | $2.48B | $2.47B | $1.85B | $1.85B | $1.85B | $1.85B |
| Total assets | $1.22B | $1.37B | $936.0M | $998.3M | $1.08B | $881.6M |
| Total liabilities | $3.72B | $3.64B | $3.01B | $2.92B | $2.86B | $2.52B |
| Shareholders' equity | -$2.50B | -$2.27B | -$2.08B | -$1.92B | -$1.78B | -$1.64B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology